Compare DAKT & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | VOR |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.5M | 767.4M |
| IPO Year | 1996 | 2021 |
| Metric | DAKT | VOR |
|---|---|---|
| Price | $19.78 | $14.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $45.33 |
| AVG Volume (30 Days) | 294.6K | ★ 1.3M |
| Earning Date | 03-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $608,932,000.00 | N/A |
| Revenue This Year | $12.06 | N/A |
| Revenue Next Year | $9.16 | N/A |
| P/E Ratio | $26.55 | ★ N/A |
| Revenue Growth | ★ 6.89 | N/A |
| 52 Week Low | $12.37 | $0.13 |
| 52 Week High | $28.27 | $49.95 |
| Indicator | DAKT | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 44.43 |
| Support Level | $19.76 | $11.74 |
| Resistance Level | $20.67 | $14.73 |
| Average True Range (ATR) | 0.53 | 1.11 |
| MACD | 0.17 | -0.27 |
| Stochastic Oscillator | 48.21 | 12.47 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.